NCT01803399 - A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers | Biotech Hunter

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Infections, Bacterial

Interventions

DRUG

GSK1322322 1200 mg

GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes

DRUG

GSK1322322 3000 mg

GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes

DRUG

Placebo

Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes

DRUG

Moxifloxacin

Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally